Stocks股票 / Health Care / BIO
BIO US listed · USD美股 · 美元
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.Bio-Rad Laboratories, Inc. 是一家美国开发制造商,为生命科学研究和临床诊断市场提供专业科技产品。
Company news公司新闻
The latest reporting最新报道
One story, with the reporting behind it.将同一事件汇总,保留各来源报道。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-10-26Earnings财务业绩
next report下次财报 2026-11-04Estimates being raised — 4 analysts预期上调 — 4 位分析师
Mixed — beat 1 of last 4 quarters表现不稳 — 近 4 季中 1 季超预期
Post-earnings drift: +10.6% (20d)财报后漂移:+10.6%(20日)
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 -6.0%
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Debt coming due到期债务
FY2025 10-KIn the 12-month bucket following fiscal period end 2025-12-31, it reported $1.3M due — about 0% of its disclosed principal.在财年期末 2025-12-31 之后12个月的区间内,已披露到期本金为 $1.3M,约占其披露本金的 0%。
All maturity buckets are measured from fiscal period end 2025-12-31, not from today.所有到期区间均从财年期末 2025-12-31 起算,而非从今天起算。
Cash reported at 2025-12-31: $529800000.截至 2025-12-31 披露的现金:$529800000。 Operating cash flow exceeded or equaled equipment spending over 2025-01-01 to 2025-12-31; no cash burn to measure.在 2025-01-01 至 2025-12-31 期间,经营现金流不低于设备支出,无可衡量的现金消耗。
Cash reported at 2025-12-31 covers 40754% of issuer-reported principal in the 12-month bucket following that fiscal period end.截至 2025-12-31 披露的现金可覆盖该财年期末之后12个月区间内发行人已披露到期本金的 40754%。
Cash shortfall against that reported principal: $0相对该已披露本金的现金缺口:$0。
Sources and cash-flow calculation来源与现金流计算
Figures are XBRL facts from one filing — no two years are mixed. Filing数据取自同一份文件中的 XBRL 事实,不跨文件拼接。文件
0000012208-26-000010, period ending报告期截至 2025-12-31, unit单位 USD.
Cache acquired缓存获取时间: 2026-10-23T08:00:12.927974+00:00.
6/6 buckets reported.个区间有披露。
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwoLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0000012208-26-000010 · Filed提交日期 2026-02-13.
Cache acquired缓存获取时间: 2026-10-23T08:00:12.927974+00:00 · Evaluated as of评估截至 2026-10-26.
- Reported operating cash flow已披露经营活动现金流: $532200000
- Reported equipment spending (capex outflow)已披露设备支出(资本开支流出): $157600000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流(经营现金流减资本开支): $374600000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变,不包括债务偿还、受限现金调整与未来融资。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Signal history信号历史
engine events引擎事件Company profile公司档案
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.Bio-Rad Laboratories, Inc. 是一家美国开发制造商,为生命科学研究和临床诊断市场提供专业科技产品。
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | +4.6% | -0.4% |
| 1 Month近1月 | -2.4% | -1.0% |
| 3 Months近3月 | +17.6% | +3.1% |
| 6 Months近6月 | +28.5% | +7.0% |
| Year to date年初至今 | +21.2% | +12.1% |
| 1 Year近1年 | +9.2% | +14.4% |
| 3 Years近3年 | +21.8% | +86.0% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $2.5B | $2.9B | $2.8B | $2.7B | $2.6B | $2.6B |
| EPS每股收益 | $126.20 | $140.56 | $-121.79 | $-21.82 | — | $27.85 |
| Free cash flow自由现金流 | $476M | $536M | $82M | $218M | $290M | $375M |
| Gross margin毛利率 | 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% |
| Net margin净利率 | 149.5% | 145.3% | -129.5% | -23.9% | -71.9% | 29.4% |
| FCF margin自由现金流利润率 | 18.7% | 18.3% | 2.9% | 8.2% | 11.3% | 14.5% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: accruals elevated vs peers (earnings lean on non-cash items)盈利质量:应计利润高于同业(盈利依赖非现金项目)
- Working capital: working capital roughly in line with sales营运资本:营运资本与销售大致同步
- Pricing power: gross margin −4.6pts over 6 years定价能力:毛利率 6 年下降 4.6 个百分点
- Capital discipline: investment near the peer median资本纪律:投资力度接近同业中位
- Balance sheet: leverage unremarkable资产负债表:杠杆水平一般
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $2.62 | $2.34 | +12.0% |
| Mar 2026 | $1.89 | $2.77 | -31.8% |
| Dec 2025 | $2.51 | $2.57 | -2.3% |
| Sep 2025 | $2.26 | $2.30 | -1.7% |
Estimate revisions预期修正
Insiders & shorts内部人与空头
Recent fund flows近期基金流向
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 33% | -0.3% | 3 |
| Feb2月 | 33% | -4.3% | 3 |
| Mar3月 | 67% | +0.5% | 3 |
| Apr4月 | 67% | +1.0% | 3 |
| May5月 | 67% | +6.5% | 3 |
| Jun6月 | 33% | -4.7% | 3 |
| Jul7月 | 100% | +10.7% | 3 |
| Aug8月 | 100% | +17.4% | 3 |
| Sep9月 | 0% | -0.5% | 4 |
| Oct10月 | 50% | +7.5% | 4 |
| Nov11月 | 67% | +2.1% | 3 |
| Dec12月 | 33% | -3.1% | 3 |